OBJECTIVES: To research the usage of over-the-counter (OTC)
nonselective non-steroidal antiinflamaroty drugs (nsNSAID)
relating to the Guidelines and the rational use of drugs in patients
with gastrointestinal (GI) diseases, morbidity and hospitalisa-
tions. METHODS: This is a retrospective study for the period
2004–2006. The source of data was the database of Public Phar-
macy Pozarevac and Public Health Centar Pozarevac, Pozarevac
(Branicevo region; 200503 inhabitans). Type of data: the number
of GI hospitalisations and the number of patients with GI dis-
eases; DDD methodology (DDD/1000 inhabitants/day) for OTC
nsNSAID. RESULTS: The number of GI disease patients was
decreased: 9636 (2004), 7982 (2005), 7806 (2006). The decrease
was 17.16% (2005) and 18.99% (2006) compared to 2004. The
number of patients who used diclofenac or other nsNSAID with
proton pump inhibitors or H2-receptor antagonists (according to
Guidelines) was increased during opserved period: 817, 931,
...1187, respectively; with a great increase of 45.29% (2006 com-
pered to 2004). But, the number of GI hospitalisations was
increased with 10.18% (2005) and 15.06% (2006) related to
2004. The costs of GI hospitalisations were grown: 29.52%
(2005) and 121.32% (2006), compared to the costs in 2004.
Considering the utilisation of OTC diclofenac (the most frequent
used nsNSAID) in DDD unit, we may see an increase: 62,279;
65,983; 82,911, respectively 2004–2006. We assume that this
pharmacoepidemiology data is directly related to the increases of
hospitalisation load. CONCLUSION: There is an improvement
of rational drug usage related to Guidelines, but the increase of
GI hospitalisation and diclofenac self-medication pointed out
that this relation must be more persistent in Branicevo region. It
will be usefull to educate the patients and the pharmacists, about
the adverse drug reaction (ADR) of the nsNSAID. This way
would be the right modality to improve the rational drug usage
of nsNSAID aiming to improve the quality of life and decrease
costs.
TY - CONF
AU - Petrić, M.
AU - Tasić, Ljiljana
AU - Sukljević, S.
PY - 2007
UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/899
AB - OBJECTIVES: To research the usage of over-the-counter (OTC)
nonselective non-steroidal antiinflamaroty drugs (nsNSAID)
relating to the Guidelines and the rational use of drugs in patients
with gastrointestinal (GI) diseases, morbidity and hospitalisa-
tions. METHODS: This is a retrospective study for the period
2004–2006. The source of data was the database of Public Phar-
macy Pozarevac and Public Health Centar Pozarevac, Pozarevac
(Branicevo region; 200503 inhabitans). Type of data: the number
of GI hospitalisations and the number of patients with GI dis-
eases; DDD methodology (DDD/1000 inhabitants/day) for OTC
nsNSAID. RESULTS: The number of GI disease patients was
decreased: 9636 (2004), 7982 (2005), 7806 (2006). The decrease
was 17.16% (2005) and 18.99% (2006) compared to 2004. The
number of patients who used diclofenac or other nsNSAID with
proton pump inhibitors or H2-receptor antagonists (according to
Guidelines) was increased during opserved period: 817, 931,
1187, respectively; with a great increase of 45.29% (2006 com-
pered to 2004). But, the number of GI hospitalisations was
increased with 10.18% (2005) and 15.06% (2006) related to
2004. The costs of GI hospitalisations were grown: 29.52%
(2005) and 121.32% (2006), compared to the costs in 2004.
Considering the utilisation of OTC diclofenac (the most frequent
used nsNSAID) in DDD unit, we may see an increase: 62,279;
65,983; 82,911, respectively 2004–2006. We assume that this
pharmacoepidemiology data is directly related to the increases of
hospitalisation load. CONCLUSION: There is an improvement
of rational drug usage related to Guidelines, but the increase of
GI hospitalisation and diclofenac self-medication pointed out
that this relation must be more persistent in Branicevo region. It
will be usefull to educate the patients and the pharmacists, about
the adverse drug reaction (ADR) of the nsNSAID. This way
would be the right modality to improve the rational drug usage
of nsNSAID aiming to improve the quality of life and decrease
costs.
PB - Elsevier
C3 - Value in Health
T1 - Investigation of OTC nsNSAID rational use and gastrointestinal diseases
VL - 10
IS - 6
SP - A357
EP - A357
DO - 10.1016/S1098-3015(10)65268-0
ER -
@conference{
author = "Petrić, M. and Tasić, Ljiljana and Sukljević, S.",
year = "2007",
abstract = "OBJECTIVES: To research the usage of over-the-counter (OTC)
nonselective non-steroidal antiinflamaroty drugs (nsNSAID)
relating to the Guidelines and the rational use of drugs in patients
with gastrointestinal (GI) diseases, morbidity and hospitalisa-
tions. METHODS: This is a retrospective study for the period
2004–2006. The source of data was the database of Public Phar-
macy Pozarevac and Public Health Centar Pozarevac, Pozarevac
(Branicevo region; 200503 inhabitans). Type of data: the number
of GI hospitalisations and the number of patients with GI dis-
eases; DDD methodology (DDD/1000 inhabitants/day) for OTC
nsNSAID. RESULTS: The number of GI disease patients was
decreased: 9636 (2004), 7982 (2005), 7806 (2006). The decrease
was 17.16% (2005) and 18.99% (2006) compared to 2004. The
number of patients who used diclofenac or other nsNSAID with
proton pump inhibitors or H2-receptor antagonists (according to
Guidelines) was increased during opserved period: 817, 931,
1187, respectively; with a great increase of 45.29% (2006 com-
pered to 2004). But, the number of GI hospitalisations was
increased with 10.18% (2005) and 15.06% (2006) related to
2004. The costs of GI hospitalisations were grown: 29.52%
(2005) and 121.32% (2006), compared to the costs in 2004.
Considering the utilisation of OTC diclofenac (the most frequent
used nsNSAID) in DDD unit, we may see an increase: 62,279;
65,983; 82,911, respectively 2004–2006. We assume that this
pharmacoepidemiology data is directly related to the increases of
hospitalisation load. CONCLUSION: There is an improvement
of rational drug usage related to Guidelines, but the increase of
GI hospitalisation and diclofenac self-medication pointed out
that this relation must be more persistent in Branicevo region. It
will be usefull to educate the patients and the pharmacists, about
the adverse drug reaction (ADR) of the nsNSAID. This way
would be the right modality to improve the rational drug usage
of nsNSAID aiming to improve the quality of life and decrease
costs.",
publisher = "Elsevier",
journal = "Value in Health",
title = "Investigation of OTC nsNSAID rational use and gastrointestinal diseases",
volume = "10",
number = "6",
pages = "A357-A357",
doi = "10.1016/S1098-3015(10)65268-0"
}
Petrić, M., Tasić, L.,& Sukljević, S.. (2007). Investigation of OTC nsNSAID rational use and gastrointestinal diseases. in Value in Health
Elsevier., 10(6), A357-A357.
https://doi.org/10.1016/S1098-3015(10)65268-0
Petrić M, Tasić L, Sukljević S. Investigation of OTC nsNSAID rational use and gastrointestinal diseases. in Value in Health. 2007;10(6):A357-A357.
doi:10.1016/S1098-3015(10)65268-0 .
Petrić, M., Tasić, Ljiljana, Sukljević, S., "Investigation of OTC nsNSAID rational use and gastrointestinal diseases" in Value in Health, 10, no. 6 (2007):A357-A357,
https://doi.org/10.1016/S1098-3015(10)65268-0 . .
